XRCC1 and urinary bladder carcinoma: Given that the predictive value of XRCC1 polymorphisms on platinum-based chemotherapy in non-small cell lung cancer has already been validated, such as XRCC1 Arg194Trp [31], it is reasonable to conclude that Arg194Trp may play a similar role in bladder cancer.